Ranbaxy Board announces change in executive leadership

Ranbaxy Laboratories Limited (“Ranbaxy”) today announced that Mr. Atul Sobti will step down from the positions of CEO and Managing Director of Ranbaxy, effective August 19, 2010 and Mr. Arun Sawhney, currently Ranbaxy's President, Global Pharmaceutical Business, has been appointed as Managing Director, effective August 20, 2010.

Furthermore, the Board noted its sincere appreciation of Mr. Sobti’s efforts during his tenure as CEO and MD as well as for building upon the strong legacy of Ranbaxy as a premier global company.

Commenting on these changes, Tsutomu Une, the Chairman of Ranbaxy, said "We are extremely grateful for the significant contribution Mr. Sobti has made to Ranbaxy ever since he joined the company. Under his leadership as CEO and Managing Director, Ranbaxy has realized various opportunities to repeat the strong operating performance while continuing to manage key challenges.” Dr. Une also said, “We are pleased to appoint Mr. Sawhney as the Managing Director,  further advancing the company with the decades of global experience he has in the industry.”

Mr. Sawhney, with over three decades of global experience with leading Indian and global pharmaceutical companies, has held the role of President, Global Pharmaceuticals Business, at Ranbaxy, since January 2010, and has been a senior executive at the Company from April 2008, providing leadership in diverse functions to achieve optimum synergy to facilitate the business objectives of the organization. Mr. Sawhney is one of the founder members of the Pharmaceuticals Export Promotion Council (Pharmexcil) and has been an active member on the committees of the prestigious Indian Drug Manufacturer’s Association and Bulk Drug Manufacturers Association (India).

About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.